Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2006

Santarus Hands Over OTC Rights for Zegerid Products to Schering-Plough

  • Santarus granted Schering-Plough HealthCare Products exclusive rights to commercialize Zegerid® branded immediate-release omeprazole products for the OTC market in the U.S. and Canada. Schering reports that according to A.C. Nielsen, a market research firm, the OTC market for heartburn products was approximately $1.1 billion for the 12 months ending mid-August 2006.

    Schering-Plough will be responsible for the development, manufacturing, and commercialization of OTC Zegerid products with the lower dosage strength of 20 mg of omeprazole for heartburn-related indications.

    Under the terms of the agreement, which are subject to review, Santarus will receive a $15-million upfront license fee payable following the effective date of the agreement and may receive up to an additional $65 million in milestone payments upon the achievement of certain regulatory and sales milestones. Santarus will also receive a royalty, subject to adjustment in certain circumstances, on net sales of any Zegerid OTC products sold by Schering-Plough under the license agreement. A portion of these royalties will be paid to the University of Missouri pursuant to a license agreement between Santarus and the University of Missouri.

    Santarus will continue to manufacture, promote, and sell Zegerid products in both 40-mg and 20-mg dosage strengths of omeprazole for their approved prescription indications in the U.S. for proton pump inhibitor products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »